Modulating Cellular Senescence and mTOR Pathway: The Therapeutic Potential of Fingolimod in NPC Disease
2024
Fingolimod Shows Promise in Treating Niemann-Pick Type C Disease
publication
Evidence: moderate
Author Information
Author(s): Abyadeh Morteza, Kaya Alaattin
Primary Institution: Virginia Commonwealth University
Hypothesis
Can Fingolimod effectively reduce cellular senescence and neurodegeneration in Niemann-Pick type C disease?
Conclusion
Fingolimod shows significant potential as a treatment for Niemann-Pick type C disease, especially in males, by delaying disease symptoms.
Supporting Evidence
- Fingolimod pretreatment reduces cellular senescence in fibroblasts.
- Fingolimod delays muscle mass decline in NPC mouse models.
- Fingolimod improves motor neuron function in NPC mouse models.
- FTY720 shows anti-inflammatory and anti-aging effects.
- FTY720's effects were more pronounced in male mice.
Takeaway
Fingolimod might help kids with a brain disease by making them feel better and helping them move better.
Methodology
The study used both in vitro and in vivo models to assess the effects of Fingolimod on NPC disease.
Participant Demographics
The study observed sex-specific effects, with greater efficacy in male mice.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website